| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
381,510,000 |
| Market
Cap: |
169.20(M) |
| Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,480 |
| 52
Week Range: |
$0.4435 - $2.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
500,000 |
525,000 |
525,000 |
525,000 |
| Total Buy Value |
$324,050 |
$343,050 |
$343,050 |
$343,050 |
| Total People Bought |
1 |
2 |
2 |
2 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Armen Garo H |
Chairman & CEO |
• – – |
2013-08-01 |
4 |
A |
$3.84 |
$13,198 |
D/D |
3,437 |
1,595,310 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2013-07-10 |
4 |
A |
$3.75 |
$2,052,454 |
D/D |
547,321 |
1,591,873 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2013-07-01 |
4 |
A |
$3.75 |
$13,197 |
D/D |
3,515 |
1,044,602 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2013-06-14 |
4 |
A |
$3.70 |
$212,902 |
D/D |
57,541 |
991,087 |
|
- |
|
| Baysal Ozer |
Chief Business OfficerOfficer |
• – – |
2013-06-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,100 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2013-06-03 |
4 |
A |
$4.24 |
$13,199 |
D/D |
3,110 |
933,546 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2013-05-01 |
4 |
A |
$4.35 |
$13,197 |
D/D |
3,037 |
930,437 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2013-04-01 |
4 |
A |
$4.23 |
$13,197 |
D/D |
3,117 |
927,400 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2013-03-01 |
4 |
A |
$4.45 |
$13,190 |
D/D |
2,964 |
924,283 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2013-02-01 |
4 |
A |
$4.18 |
$13,184 |
D/D |
3,154 |
921,319 |
|
- |
|
| Sharp Shalini |
Director |
– • – |
2013-01-30 |
4 |
AS |
$4.36 |
$1,256 |
D/D |
(288) |
81,311 |
|
- |
|
| Wentworth Kerry |
VP, Clin, Reg & Quality |
• – – |
2013-01-28 |
4 |
A |
$4.35 |
$3,019 |
D/D |
694 |
37,410 |
|
- |
|
| Valentine Karen |
VP, General Counsel |
• – – |
2013-01-28 |
4 |
A |
$4.35 |
$1,814 |
D/D |
417 |
29,384 |
|
- |
|
| Sharp Shalini |
Director |
– • – |
2013-01-28 |
4 |
A |
$4.35 |
$2,719 |
D/D |
625 |
81,599 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2013-01-28 |
4 |
A |
$4.35 |
$1,814 |
D/D |
417 |
23,690 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2013-01-28 |
4 |
A |
$4.35 |
$6,042 |
D/D |
1,389 |
918,165 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2013-01-02 |
4 |
A |
$4.00 |
$13,197 |
D/D |
3,303 |
916,776 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2012-12-24 |
4 |
A |
$4.33 |
$1,083,699 |
D/D |
250,277 |
913,473 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2012-12-03 |
4 |
A |
$3.98 |
$13,199 |
D/D |
3,320 |
663,196 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2012-11-01 |
4 |
A |
$4.60 |
$13,199 |
D/D |
2,872 |
659,876 |
|
- |
|
| Sharp Shalini |
Director |
– • – |
2012-10-31 |
4 |
AS |
$4.40 |
$1,267 |
D/D |
(288) |
80,974 |
|
- |
|
| Wentworth Kerry |
VP Clin, Reg & Quality |
• – – |
2012-10-26 |
4 |
A |
$4.42 |
$3,072 |
D/D |
695 |
36,716 |
|
- |
|
| Valentine Karen |
VP General Counsel |
• – – |
2012-10-26 |
4 |
A |
$4.42 |
$1,843 |
D/D |
417 |
28,967 |
|
- |
|
| Sharp Shalini |
Director |
– • – |
2012-10-26 |
4 |
A |
$4.42 |
$2,763 |
D/D |
625 |
81,262 |
|
- |
|
| Klaskin Christine M |
VP Finance |
• – – |
2012-10-26 |
4 |
A |
$4.42 |
$1,843 |
D/D |
417 |
23,273 |
|
- |
|
534 Records found
|
|
Page 9 of 22 |
|
|
